Good afternoon. Thank you for joining the Owlet First Quarter 2024 Earnings Call. My name is Cameron, and I will be your moderator today. I would now like to hand the conference over to your host, Mike Cavanaugh, from Investor Relations. You may begin.

Good afternoon, everyone, and thank you for joining us today for Owlet Baby Care, Incorporated First Quarter 2024 Earnings Call. We appreciate your time and interest in our company. Earlier today, Owlet Inc. released financial results for the quarter and full year ended March 30, 2024. The release is currently available on the company's website at www.investors.owletcare.com. Our speakers for today's call are Kurt Workman, Owlet's Co-Founder and Chief Executive Officer; and Kate Scolnick, our Chief Financial Officer. Kurt will begin with an overview of our performance and key developments, followed by Kate, who will provide a detailed review of our financial results. Following their remarks, we will open the call for your questions. Before we get started, we would like to remind participants that today's discussion will contain forward-looking statements based on current expectations. These statements are only predictions and are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, those described in our most recent filings with the SEC and in the Risk Factors section of our annual report on Form 10-K for the fiscal year ended December 31, 2024. Please note that the company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. With that, I would now like to turn the call over to our CEO, Kurt Workman.

Thanks, Mike. And also joining us on today's call is Jonathan Harris, Owlet's President and Chief Revenue Officer. Good afternoon, everyone, and thank you for joining Owlet's earnings call today. As always, we appreciate your ongoing support of Owlet. We're starting off the year with strong double-digit revenue and sell-through growth, gross margin expansion, significant operating cost savings, and adjusted EBITDA improvement over last year. In addition to our significant Q1 operational achievements, we met our business objectives in our healthcare business as we launched our go-to-market channels to include medical device sales and have now integrated our first telehealth partnerships with Wheel on owletcare.com. Our recent announcement of CE Medical authorization in Europe, in addition to the recent FDA clearances, are a powerful endorsement of our technology, establishing Owlet as a leader in safe and effective health monitoring for infants. There is robust and discernible momentum for Owlet in the market. We believe this year is the turning point propelling us to our vision of a safe and healthy journey for every baby and a sustainable growth company. In 2024, we have 3 main growth objectives. First, with the first FDA-cleared monitor on the market, now is the time to drive significant adoption of the Dream Sock. Second, with the approval of BabySat, we are opening medical distribution channels to directly serve the babies who need the convenience and reliability of Owlet the very most with insurance reimbursement. Finally, we will be launching our new subscription service this year, leveraging our vast and growing dataset to help guide parents through health and sleep challenges they face when caring for their newborn. I'll turn the time over to Jonathan Harris, our President and Chief Revenue Officer, to talk about the first 2 areas of focus for 2024, accelerating adoption in our new medical sales channels.

Thanks, Kurt. I've been fortunate enough to be a part of numerous hypergrowth companies such as GoPro and Jawbone, and some of the key parallels I'm seeing with Owlet are the passion for the brand by the core audience and a strong word of mouth sharing their story with the global audience. As Kurt just mentioned, we have some really strong momentum building, not only in the U.S. but across the globe. I'd like to start with adoption. The response to the new FDA-cleared Dream Sock here in the U.S. has been outstanding. We've witnessed strong parental engagement with over 30 million organic views of our video content across TikTok and Facebook in the first quarter and over 1.3 million followers across our social channels. The early response to the FDA clearance of Dream Sock has been strong, with sell-through achieving over 60% growth compared to Q1 of 2023. Customer satisfaction supports this growth with NPS scores exceeding 70 and Dream Sock hitting an all-time high in this category. We achieved this market enthusiasm while maintaining a strong growth trajectory, including 50% gross billings growth and 35% revenue growth over Q1 last year. Here in the U.S., our partnerships with major retailers, Target and Walmart, are growing with expanded merchandising and placements to bring the Owlet experience to life. Specifically, we are seeing sell-through at Target increase by over 31% year-over-year, and our baby list registries grew at over 64% versus the previous year, proving our messaging is resonating with expecting parents. Owlet is still in the beginning stages of growth for Dream Sock, with about 8% of the 3.6 million births every year going home with an Owlet Sock. We believe that just like car seats, breast pumps, and strollers, every baby will have access to health sensing technology at home. I'm also very excited to announce that we recently obtained CE medical clearance, clearing the way for Owlet to increase reach in the significant European market where over 3.8 million babies are born every year, although it's extremely well positioned to take advantage of our EU clearance with key retail partnerships across the European market, U.K., and into Australia, where we're already seeing sell-through up significantly. For example, at Baby Bunting, Australia's largest baby retailer, we saw year-over-year sell-through increase of over 200% of Owlet products. Our partners are helping us share our story globally within their markets and in their own languages. We expect continued growth and momentum as we launch Dream Sock as a medical device across these regions. This exciting growth opportunity comes on the back of continuing operating discipline. In 2023, we honed our efficiency, showing an impressive near 80% reduction in CPA cost per acquisition compared to prior periods, down to a lean $22. This efficiency extends throughout operations, improving our gross margin by 500 basis points over Q1 2023. We've also maintained disciplined control over operating expenses, holding steady at roughly $10 million per quarter, excluding stock-based compensation. All of this demonstrates our commitment to maximizing growth while moving decisively towards profitability. Secondly, opening new medical channels. The response from pediatricians to Owlet's BabySat has also been overwhelmingly positive. In the first 3 months, we've seen hundreds of pediatricians prescribing BabySat. The feedback we are receiving from doctors tells us that BabySat is a powerful new tool, which enables not only remote monitoring of babies under their care but also informs more effective ongoing disease management of various conditions. We launched our partnership with AdaptHealth in Q1 to expand our distribution in medical channels. Adapt serves as a cornerstone for successfully entering this vital market. We've integrated with all major insurance plans, including Aetna, Cigna, United, and many of the BlueCross networks, removing barriers and ensuring families can access BabySat when they need it most. We're also streamlining adoption through partnerships with providers like Wheel, offering telehealth services directly through owletcare.com for prescription access. Parents can now seamlessly get a prescription and submit for reimbursement through the Owlet website with nearly 70% of private insurers integrated with BabySat. AdaptHealth then handles all the verification and fulfillment of the BabySat device as a nationwide DME. We've also begun educational teach-ins to Adapt's large sales force with relationships across over 100 hospitals. We expect this channel will take some time to mature, but we see this as a very large opportunity to offer families with medical necessity, our innovative technology reimbursed through insurance. In 2024, we'll continue to add new distribution partners to help us reach every baby as they leave the hospital. I'll now turn it back over to Kurt to talk about our product development efforts with subscription.

Thanks, Jonathan. In addition to our channel expansion, we're also focused on driving additional value to our customers through a new subscription service. Our unparalleled dataset, informed by capturing over 1 trillion baby heart feeds, provides deep insights into infant health and sleep, and we're unlocking its potential. Parents lose over 44 nights of sleep in the first year alone, and there are over 92 million healthcare visits for kids aged 0 to 4 years old. We're navigating these challenges, and parents want to know what's normal and when they need to get professional support. Parents want access to information that can help them better navigate when to visit the doctor and when to stay home, and they want the ability to seamlessly share that information with a doctor from the comfort of their home. They also want information that can help them personalize sleep coaching for their baby. Health and sleep are the fundamental concerns of every parent. Our subscription service will analyze this data to offer parents personalized recommendations and support. Engineering work on the service is progressing rapidly, and we expect the beta launch this summer that parents can subscribe to for an additional monthly fee. We believe this subscription will address real pain points for families, creating a compelling and valuable monthly offering. Apart from offering data and insights to parents during the initial year of their child's life, we firmly believe that our products and services can extend their value well into the toddler years and beyond by focusing on core parenting pain points in health and sleep and leveraging our data to drive continued releases of software features. We believe this can expand our TAM and significantly extend our LTV per customer. Owlet is in a stronger position than ever. We're a growth-oriented company operating efficiently and bringing innovative solutions that address the fundamental needs of parents. With our landmark FDA clearances, we are established as a pioneer in infant health technology. This unique set of circumstances has the company poised for success, and we continue to deliver value for our families and stakeholders alike. Thank you. We're excited to share this incredible journey with you. I'm now going to turn the time over to Kate for the financials.

Thank you, Kurt, and thanks to everyone joining us today. In Q1 2024, Owlet demonstrated strong financial performance. I'll spend the next few minutes walking through Owlet's key financial metrics and providing some additional detail. Gross billings for the first quarter were approximately $18.4 million, up over 48% year-over-year. Product promotions and discounts were $2.2 million. And returns on allowance reserves were $1.4 million, approximately 8% of gross billings within our average range. Q1 net revenue, which includes promotions, discounts, and returns and allowances, was approximately $14.8 million, up over 37% year-over-year. Revenue growth was primarily driven by higher sales of Dream Sock products, reflecting an increase in consumer demand and sell-through as compared to the same period in the prior year. Our gross margin for the first quarter was approximately 44.4%, up from 38.7% margins in Q1 of last year. Gross margins increased year-over-year primarily due to higher revenue and lower direct product and fulfillment costs. During the quarter, we experienced some cost of goods expense impact from elevated transportation costs related to the global disruptions in inventory routing. Along with other companies seeking shipping alternatives, we're working to mitigate these factors. Operating expenses in the first quarter were approximately $12.3 million, including stock-based compensation of $2.2 million, representing a 19% decrease in operating expenses year-over-year. Operating costs decreased year-over-year primarily due to transaction costs and lower spend in G&A to support the business. Excluding stock-based compensation, Q1 operating expenses were approximately $10.1 million. First quarter net income was approximately $3.3 million for the quarter compared to a net income loss of approximately $11.9 million in Q1 2023. Net income in the first quarter of 2024 was primarily driven by demonstrating stronger operating results over last year and a gain related to the company's common stock warrants outstanding of approximately $9.2 million from a decrease in the fair value of common stock warrants outstanding. This compared to a gain of approximately $1.9 million in the fair value of common stock warrants outstanding in the first quarter of 2023. Adjusted EBITDA loss for the first quarter was approximately $3.1 million, improving approximately 46% from adjusted EBITDA loss of approximately $5.8 million in Q1 of last year. Turning to the balance sheet, Q1 ended with approximately $18.4 million in cash and cash equivalents, including the $9 million financing announced in February, providing us with good financial flexibility to execute on our 2024 growth initiatives and the necessary working capital resources to meet the growing customer demand for FDA-cleared products. We remain focused on executing on our strategic initiatives to further strengthen our commercial and financial performance in 2024, and the year is off to a strong start. Looking ahead, we will be refraining from providing specific quarterly revenue guidance. We are focused on executing on the core business activities in 2024 that will maximize the following initiatives: supporting Dream product commercialization globally and driving a continual balance of sell-in and sell-through consumer retail inventory. From a sell-in linearity perspective, we anticipate a seasonal sell-in revenue increase from Q1 to Q2 for Mother's Day holiday promotions and Prime Day. Following Q2, selling to retailers for the November-December holiday seasonal promotions usually takes place in Q3. Continuing to make effective strides in BabySat commercialization with new DME partnership and Wheel integration on owletcare.com. As a reminder, we anticipate BabySat product revenue will be ramping in 2024 as we develop these partnerships, which will align for revenue impact in 2025. Focusing operationally on driving gross margins within our target range of 45% to 50% through unit volumes, product mix, and operational efficiencies in driving leverage in our business operations towards breakeven and sustainable profitability. Through 2024, we are targeting operating expenses excluding stock-based compensation between $10 million to $12 million per quarter.

I wanted to discuss the quarter itself. The gross billings growth of 50% appears very impressive. I'm curious, given that we're coming off somewhat low levels, how does that compare to levels before the FDA warning letter? I'm trying to understand if we have returned to pre-warning letter levels yet.

We're getting really close. Charles, thanks for the question, and I'll let Kate kind of follow on with this. But yes, we're getting closer to that. I definitely wouldn't say Q1 is all the way back to smart stock levels, but we're seeing the demand there. We're seeing the growth, and we believe that we'll be able to surpass that. But we're not quite there yet.

Yes, I agree with his comment too, and yes, great.

We're doing a lot of work. I just going to say we're doing a lot of work to build the word of mouth this quarter. It's kind of we launched both devices at the beginning of Q1 and have done a ton of work to build demand and word of mouth in the market. And we're seeing that really take hold. We're building the medical distribution channels. We're updating POP and all the retail channels. We're updating our registry programs. We're seeing registries grow. So all the signs point in the right direction, and this is our first quarter kind of back in the market with now the FDA clearance.

Got it. It's encouraging to hear the positive feedback on BabySat and that physicians are already considering prescriptions. Could you provide some details about your DME partnership with AdaptHealth? Is everything fully operational? Are physicians able to access the product? Considering your earlier comments, Kate, you mentioned that a significant contribution is expected more in 2025. Is there any reason we might not see more benefits this year?

Yes, I'll take the first part, Charles. Thank you for the question. Yes. So we are fully up and running. We launched with AdaptHealth at the beginning of Q1, and then we launched with our Wheel integration, our Telemed for prescription. So we are seeing those numbers increase dramatically. In addition, we are beginning at the early stages of healthcare reimbursement, insurance reimbursement, and we really see that as a driving factor. So Adapt has been a fantastic partner, really helping us get up and running. But as you know, the medical community and healthcare take a little bit longer than consumer. So we are definitely building that, and we're driving it to be conservative, but we're very optimistic about where we're going, the direction we're heading, and the feedback we're hearing so far.

Got it. Just to clarify, there are existing reimbursement codes that you're going to apply for BabySat, right? You're not waiting for the creation of any new codes?

No, that is totally correct. What we're doing now is just bringing on more insurance partners.

Okay. Awesome. And then, Kate, can you remind me, you talked about sort of promotion levels. Obviously, we're going to have greater promotions in Q2 for Mother's Day and ahead of Prime Day. Can you remind me on a relative basis, I think you said for 1Q, promotions were about $2.2 million. Does that double in Q2? How should we think about sort of net revenue in 2Q relative to 1Q perhaps?

Yes. Typically, for promotions, we set aside a reserve that varies based on timing. We also consider that Mother's Day falls within this period. The main factor for our sequential growth is when we prepare for Prime Day, as that can influence our Q2 results. Regarding the differences between gross and net figures, we've indicated there is an average 8% difference. For our sequential outlook from Q1 to Q2, we anticipate returning to a healthy run rate.

For revenue?

Yes, for gross sales.

Yes. Okay. All right. And then if I could ask, obviously, there was an announcement, I think, today Masimo just also received FDA approval for an over-the-counter monitoring product. Maybe can you talk about sort of how a second product in the market would mean for you guys? Could that be actually a good thing because the category itself is growing? Maybe it gives you something to compare yourself against? Maybe thoughts on that? And then maybe sort of remind us sort of how your relationship with Target and Amazon work? Is there any exclusivity with Target perhaps that would keep the Masimo product off the shelves? Or any kind of color there would be helpful.

Thank you, Charles. I'll address the first part, and then Jonathan can add at the end. This is a huge market. We noted today that there are 3.6 million babies born each year in the U.S. and 3.8 million in Europe. Owlet has pioneered this category; we built it, are expanding it, and are leading it. We currently offer two FDA-cleared products and have just announced our CE Med Mark. Our brand awareness is at an all-time high, and we believe our product features and trusted technology distinguish us. We clearly lead this category and have established a significant distribution network with our channel partners. We anticipate that other health monitors in our space will require similar approvals, and the entry of Masimo serves as validation for the category. We believe that eventually, every baby will have access to health sensing technology like Owlet, and we will continue to lead in this area. Additionally, we are addressing any intellectual property concerns as they arise. Most importantly, we will continue to innovate and lead the category for parents. Regarding our distribution with Target, Walmart, and other retailers, we have secured improved placements across all channels. We possess the largest footprint and the strongest brand awareness and reputation. When parents consider purchasing a health monitor, Owlet is top of mind. That is our primary focus. Jonathan, do you have any additional comments?

No. I would just expand on the relationship and the partnership with our major retailers, not only here in the U.S. but also internationally and really driving that relationship and the Owlet brand and word of mouth amongst parents, not only the parents who are using our products but them speaking to new parents coming in, newly expecting parents is a strong driver for us.

Great. And maybe, Kate, one last question for you here is I know you're not really giving formal full-year guidance. But maybe just to help folks think about sort of trajectories in terms of revenue as we move through the course of this year, sort of any high-level thoughts as you think about this year and then going forward. And then obviously, with the profitability, I think last quarter, ex onetime items, you would have been positive. This quarter, we're still down a couple of million bucks. Maybe give us a sense for trajectory on profitability as well. That would be helpful.

Yes. We believe we are beginning this year on a strong note, particularly with the two domestic clearances for both of our core products. Additionally, we recently received the CE-Mark internationally, which is crucial for our business. These opportunities are significant for us. As mentioned, we will be introducing a new product with a subscription model, and we aim to be well ahead of last year's performance. Last year, we faced specific challenges related to waiting for clearances and issues with some customers that we do not expect to encounter again this year. We are targeting strong double-digit revenue growth. The second and third quarters will provide clarity on these opportunities. More importantly, we believe establishing BabySat with the partnerships mentioned and launching the subscription this summer will create momentum heading into 2025, beyond what we achieve in 2024. We are enthusiastic about the potential for increased profitability. Our focus remains on moving towards positive adjusted EBITDA. We have sustained operating expenses between $10 million and $12 million, excluding stock-based compensation, with minimal spending on discrete items. We are making an effort to control employee costs, hiring, and discretionary expenditures. As we explore revenue opportunities, we anticipate leveraging our business model effectively. We are committed to reaching these higher growth revenue levels as the year progresses.

Great. Appreciate all the comments. Thanks, everyone.

Thanks, operator. First question is for Kate. Can you please give us an update on your investor outreach efforts and how you're engaging investors in the Owlet stock?

Yes, sure. So as we've just been talking about, first and foremost, is delivering strong operational results and communicating on that execution. We've been talking about our financial results, our growth objectives and accomplishments around our products, around our channels, both domestically and internationally, our regulatory clearances, and then growing that investor engagement. So we've been growing our presence, both virtually and in person. We've announced a number of conferences that we've had in Q1 and Q2 here. So look for more opportunities as we head through the year.

Great. Thanks. Next question for the team. Can you please discuss the growth plan in terms of new product pipeline, new channels and new marketing efforts.

Yes, I'll address that. This is Jonathan. We've covered a lot of this already, but I want to emphasize our focus on the retailers we currently work with. We're expanding our in-store merchandising at Target and over 1,000 Walmart stores to enhance the Owlet experience for parents and those expecting a child. Additionally, we're ramping up our marketing efforts to share stories from our customers with new parents, highlighting how Owlet has provided better parenting insights and peace of mind. We're committed to sharing the narratives of our existing parents and customers. Regarding channel growth, we've touched on our international expansion, which is vital for us, particularly with our CE clearance and medical sales channels. We're currently partnered with AdaptHealth and National DME, which will give parents direct access to BabySat, often with full insurance reimbursement for the product. Lastly, we're focusing on our subscription service to extend customer lifetime value by providing data and insights to parents during the first year of their child's life. We strongly believe our products and services can continue to offer value well into the toddler years and beyond. We see a solid distribution partnership here and internationally, and we're committed to advancing our medical channels and enhancing our subscription services.

Great. And last question for the team. So can you tell us where you are in terms of working with health insurance providers to secure reimbursement for BabySat?

Yes. As we previously mentioned, through AdaptHealth with our BabySat product, we've integrated with many major insurance plans, including Aetna, Cigna, United, and various BlueCross networks. We are focused on expanding our DME and provider partnerships, as well as integrating with Medicare and Medicaid to ensure that every baby who needs Owlet has the opportunity to access it.

Great. Thanks, Jonathan. That is all the questions we have. I think with that, we can turn it back over to Kurt Workman for final remarks.

Thanks, Mike. Thanks for joining us today. It's been an exciting journey for Owlet, and we are grateful for the continued support. I'd like to take this opportunity to thank our talented team for their incredible dedication and hard work. Your commitment to our mission and drive for innovation is just inspiring. We've achieved significant milestones this quarter, demonstrating strong financial performance and continued growth. As we move forward, we remain focused on executing our strategic initiatives to further strengthen our commercial and financial performance, and we're confident that our innovative solutions, unwavering commitment to quality and passionate team will continue to drive success for Owlet. Thank you again for your trust and partnership.

That concludes the Owlet's First Quarter 2024 Earnings Call. Thank you for your participation.